MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed a Memorandum of Understanding with CBD Vida LTDA, who plans to launch an ease-of-access skin scanning/assessment program throughout Brazil, using MedX’s DermSecureTM. Telemedicine platform.
"There is a significant opportunity for MedX’s skin imaging technology in Brazil, as skin cancer is the most common type of cancer in Brazil,” stated Fabio Camata Candello, CBD Vida LTDA’s CEO. More than one hundred thousand new cases of skin cancer were recorded in Brazil between 2016 and 2017, according to the Brazilian Cancer Institute, and almost 6,000 were classified as melanoma, an aggressive form of the disease that can spread to other parts of the body. A recent study shows that Brazilian melanoma patients experienced a lower survival rate than the current worldwide average. The high prevalence of advanced cases reinforces the importance of local strategies to diagnose melanomas in the early stages, and to treat it definitively. “MedX’s DermSecureTM telemedicine platform and advanced SIAscopy imaging technology is a perfect solution for early detection," further noted Mr. Candello.
"CBD Vida LTDA’s experience in marketing medical devices and health solutions in the Brazilian market, as well as their deep connectivity with major pharmacies and medical clinics will be a big benefit as they enter into this large market, and we are delighted to be partnering with them,” noted Scott Spearn, President & CEO of MedX “
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
About CBD Vida LTDA
The founders of CBD Vida Canada, combined with their CBD Vida LTDA partners in Brazil form a partnership that brings decades of professional business development, training and experience. CBD Vida LTDA’s business relationships in Brazil are extensive and cover pharmaceuticals, medical clinics, and pharmacies, legal, regulatory, governmental, and private industry. These relationships provide a synergy between Brazil & Canada that will ensure expedited market entry for this life saving solution.
The partners understand the importance of Brazil on the world market, with it being the second largest importer of medical devices in the world. CBD Vida LTDA’s relationship with MDX Health and their rapid skin assessment solution, combined with their corporate & business experiences, will give the Brazilian population an opportunity to dramatically reduce the mortality rate currently being experienced by late the late detection skin cancer. CBD Vida LTDA has the capability and commitment to open the Brazilian market rapidly and help our fellow Brazilians with this preventable cancer.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
